Lineage Cell Therapeutics, Inc.

LCTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $1.9M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $-3.2M
SG&A Expense $-2.3M
Operating Income $-3.5M
Operating Margin -182.9%
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-5.1M
Net Margin -267.2%
EPS (Basic) $-0.18
EPS (Diluted) $-0.18
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 3 of 3 Older →